Clinical Trial Search

Primary: Visual Analog Scale Pain Score Assessment (VAS) — 2.96; 3.24 score on a scale

Primary: Intraocular Pressure (IOP) — -4.2 mm Hg

Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants

Primary: Number of Participants With Resolution of the Direct Hyperbilirubinemia — 29 Participants

Primary: Number of Participants With Aggression as Per the Cohen Mansfield Agitation Inventory, Aggression Subscale — 29; 23 Participants — p=0.29

Primary: Change From Baseline to Week 12 in Maturation Value (MV) After 12 Weeks of Treatment — 26.9; 3.2 vaginal health index — p=<0.001

Primary: Number of Patients With Tattoo Clearance — 3; 5 Participants

Primary: Change in Sweating Assessed Using Gravimetry — -104.50; -90.85 mg

Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days

Primary: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to…

Primary: Safety: Proportion of Subjects With Grade 3 Solicited and Unsolicited General Reactions After Vaccination of RTS, S/AS02A and RTS, S/AS01B — 0; 1 participants

Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) — 2656.5; 2469.7; 2690.6 h•μg/mL

Primary: Change From Baseline in California Verbal Learning Task Score — 3.04; 5.17; 4.22; 7.04 score on a scale

Primary: Subjective Scores of Comfort at Insertion After 4 Weeks of Comfilcon A Use — 89.9 units on a scale

Primary: Change in Proportion of Days Used Outside of Controlled Environment — .27; .35; .35; .32 proportion of days used — p=.12